| Phase 2 trial of daratumumab, ixazomib, lenalidomide and modified dose dexamethasone in patients with newly diagnosed multiple myeloma P Kapoor, MA Gertz, B Laplant, GC Malave, E Wolfe, E Muchtar, ... Blood 134, 864, 2019 | 16 | 2019 |
| Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma JP Abeykoon, J Vaxman, SV Patel, S Kumar, GC Malave, KS Young, ... British journal of haematology 199 (1), 95-99, 2022 | 15 | 2022 |
| Daratumumab, ixazomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma SK Kumar, P Kapoor, B Laplant, L Phuong-Dung, E Muchtar, FK Buadi, ... Blood 136, 36-37, 2020 | 4 | 2020 |
| Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma GC Malave, P Kapoor, A Dispenzieri, MA Gertz, MQ Lacy, SR Hayman, ... Blood 134, 5833, 2019 | | 2019 |
